does retatrutide cause cancer GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management Phase III retatrutide study demonstrates

More than a thousand cases of the disease, and 19 deaths, have been linked to GLP-1s.

Beyond these, in the pre-clinical space, over 25 candidates have been disclosed, but our analysis of patents, company disclosures, and early-stage publications identifies nearly 70 additional undeclared pre-clinical programs

GLP-1116

Additionally, GLP-1 agonists improve metabolic functions by increasing the production of short-chain fatty acids like butyrate, propionate, and acetate, which serve as energy sources for colonocytes, modulate immune responses, and enhance the production of gut hormones that regulate appetite and glucose homeostasis

GIP (glucose-dependent insulinotropic polypeptide) receptors

And it's clear that these medications have significant potential to not only meaningfully improve patient outcomes, but also to reshape the business models underlying chronic care today